Sanofi Stock Forms Golden Cross As Dupixent Eyes FDA Green Light: Can The Bullish Run Continue?
Sanofi stock is surging with a Golden Cross formation and promising Dupixent results. With FDA review and potential approval, investors are excited.
WMTW on MSN1d
Maine announces settlement to reduce insulin costs
Maine Attorney General Aaron Frey announced a settlement agreement Tuesday with Sanofi-Aventis U.S. following scrutiny over the company’s pricing of insulin products. Sign up for our Newsletters Under ...
Bizcommunity7d
SA competition watchdog probes Novo Nordisk and Sanofi over insulin
South Africa's Competition Commission is investigating drugmakers Novo Nordisk and Sanofi over possible anti-competitive ...
Devdiscourse13d
Breakthrough Heart Drug Ataciguat Shows Promise in Aortic Valve Stenosis Trials
An experimental drug, ataciguat, initially created by Sanofi and further developed by the Mayo Clinic, has significantly ...
BioPharma Dive17d
Sanofi, Teva add to case for new bowel disease drug
Detailed trial results could help Sanofi and Teva Pharmaceuticals make a case that a drug they’ve been developing will be competitive with rival treatments from Merck & Co. and Roche. The data, ...
Pharmaceutical Technology22d
Sanofi moves closer to selling controlling stake in $17bn-valued Opella
Opella is well-known in France for manufacturing the painkiller Doliprane. Image credit: Shutterstock / Leitenberger Photography. Sanofi’s sale of its $17bn consumer health business Opella just ...
Yahoo Finance23d
FDA to review Sanofi and Regeneron’s Dupixent sBLA for bullous pemphigoid
Sanofi and Regeneron’s blockbuster biologic Dupixent (dupilumab) is poised for yet another label expansion, this time for the rare autoimmune skin disorder bullous pemphigoid (BP). The US Food ...
Pharmaceutical Technology23d
FDA to review Sanofi and Regeneron’s Dupixent sBLA for bullous pemphigoid
Regeneron and Sanofi have collaborated on Dupixent since 2007. Credit: The Washington Post via Getty Images. Sanofi and Regeneron’s blockbuster biologic Dupixent (dupilumab) is poised for yet another ...
Pharm Exec24d
FDA Approves Sanofi’s Rapid Acting Insulin Biosimilar Merilog for Diabetes
The FDA has approved Merilog (insulin-aspart-szjj), a biosimilar to Novolog (insulin aspart), for improving glycemic control in adults and pediatric patients with diabetes mellitus. The regulatory ...
BioSpace24d
Sanofi Challenges Novo With First FDA Nod for NovoLog Biosimilar
In March 2023, Sanofi and Novo came under fire from Sen. Bernie Sanders (I-Vt), who asked the companies to follow in the footsteps of fellow diabetes leader Eli Lilly and lower the price of their ...
Business Insider26d
FDA approves Sanofi biosimilar product for treatment of diabetes
The FDA granted approval of Merilog to Sanofi (SNY)-Aventis U.S. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top ...
Seeking Alpha27d
Alnylam: Waiting For Regulatory Updates In March
Alnylam's Amvuttra and partner Sanofi's fitusiran have PDUFA dates with the FDA next month, and approvals should create new revenue sources for the company. Alnylam's 2025 guidance for the TTR ...